MORPHOFUNCTIONAL PECULIARITIES OF THE MYOCARDIUM AND CORONARY MICROVASCULATURE IN EXPERIMENTAL PULMONARY-ARTERY BRANCHES EMBOLISM

Functional parameters of the heart ventricles, subendocardial morphology of anterior and posterior walls (AW and PW) of the right and left ventricles (RV and LV) and the state of coronary microvasculature were studied in experimental research on chinchilla mature rabbits at early (1, 2, 3 days) and late (after 7 and 30 days) stages after pulmonary artery branches embolism (PABE) which had been established by means of vaseline oil injection (0.3 ml/kg) in marginal ear vein. It was found that the heart muscle responded as a whole to the RV overload in PABE, with the structural and functional changes of both ventricles. LV damage develops in parallel with the restoration of the RV reserve possibilities and is more significant and prolonged in the LV PW. Positive correlation exists between the blood supply level of both ventricles PW and the interventricular pressure changes

MORPHOFUNCTIONAL PECULIARITIES OF THE MYOCARDIUM AND CORONARY MICROVASCULATURE IN EXPERIMENTAL PULMONARY-ARTERY BRANCHES EMBOLISM

Functional parameters of the heart ventricles, subendocardial morphology of anterior and posterior walls (AW and PW) of the right and left ventricles (RV and LV) and the state of coronary microvasculature were studied in experimental research on chinchilla mature rabbits at early (1, 2, 3 days) and late (after 7 and 30 days) stages after pulmonary artery branches embolism (PABE) which had been established by means of vaseline oil injection (0.3 ml/kg) in marginal ear vein. It was found that the heart muscle responded as a whole to the RV overload in PABE, with the structural and functional changes of both ventricles. LV damage develops in parallel with the restoration of the RV reserve possibilities and is more significant and prolonged in the LV PW. Positive correlation exists between the blood supply level of both ventricles PW and the interventricular pressure changes

The need to strengthen measures for the diagnosis and treatment of Helicobacter pylori infection in Russia. Memorandum

Leonid B. Lazebnik, PhD, Doctor of Medical Scienses, Professor, Department of Polyclinic Therapy; President of Gastroenterological Scientific Society of Russia; Vise President of Russian Scientific Medical Society of Therapists; Scopus Author ID: 7005446863, ORCID: 0000-0001-8736-5851 Dmitry S. Bordin, MD, PhD, Head of the Department of Pancreatic, Biliary and upper digestive tract disorders; professor of the department of general practice (family medicine); professor of the department of propaedeutics of internal diseases and gastroenterology; ORCID: 0000-0003-2815-3992 Nataliya N. Dekhnich, Doctor of Medical Sciences, Associate Professor at the Department of Faculty Therapy; ORCID: 0000-0002-6144-3919 Roman S. Kozlov, Professor, Corresponding member of the Russian Academy of Science, Director, Institution of Antimicrobial Chemotherapy; chief freelance specialist-therapist of the Ministry of Health of Russia for the Siberian Federal District, professor Mariya A. Livzan, D. Sci. (Med.), Professor, Rector, Head of the Department of Faculty Therapy, Occupational Diseases; ORCID: 0000-0002-6581-7017, Scopus Author ID: 24341682600 Elena A. Lyalyukova, PhD, MD, Professor of the Department of additional postgraduate education in internal and family medicine, Associate Professor; WoS Research ID: AAB -5416-2021, Scopus Author ID: 56657486600, ORCID: 0000-0003-4878-0838 Svetlana V. Luzina, Deputy Chief physician for Medical Part Galina V. Belova, MD, PhD, Professor, Deputy chief physician; Scopus Author ID: 57198379175 Rustem A. Abdulkhakov, Doctor of Medicine, Professor of the Department of Hospital Therapy, Kazan State Medical University, Ministry of Health of Russia, Professor; ORCID: 0000-0002-1509-6776, Scopus Author ID: 6506615710 Sayyar R. Abdulkhakov, Candidate of Medical Sciences, Associate Professor, Head of the Department of Fundamental Foundations of Clinical Medicine; Institute of Fundamental Medicine and Biology; Associate Professor, Department of General Medical Practice and Polyclinic Therapy; assistant professor

Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: A randomized, placebo-controlled, double-blind study (RUSSLAN)

Aims: To evaluate the safety and efficacy of levosimendan in patients with left ventricular failure complicating acute myocardial infarction. Methods and Results: Levosimendan at different doses (0·1-0·4 μg . kg-1 . min-1) or placebo were administered intravenously for 6 h to 504 patients in a randomised, placebo-controlled, double-blind study. The primary end-point was hypotension or myocardial ischaemia of clinical significance adjudicated by an independent Safety Committee. Secondary end-points included risk of death and worsening heart failure, symptoms of heart failure and all-cause mortality. The incidence of ischaemia and/or hypotension was similar in all treatment groups (P=0·319). A higher frequency of ischaemia and/or hypotension was only seen in the highest levosimendan dose group. Levosimendan-treated patients experienced lower risk of death and worsening heart failure than patients receiving placebo, during both the 6h infusion (2·0% vs 5·9%; P=0·033) and over 24 h (4·0% vs 8·8%; P=0·044). Mortality was lower with levosimendan compared with placebo at 14 days (11·7% vs 19·6%; hazard ratio 0·56 [95% CI 0·33-0·951; P=0·031) and the reduction was maintained at the 180-day retrospective follow-up (22·6% vs 31·4%; 0·67 [0·45-1·00], P=0·053). Conclusions: Levosimendan at doses 0·1-0·2 μg . kg-1 . min-1 did not induce hypotension or ischaemia and reduced the risk of worsening heart failure and death in patients with left ventricular failure complicating acute myocardial infarction. © 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved

The first Russian consensus on quantitative assessment of treatment outcome

The first Russian Consensus on the quantitative evaluation of treatment results was approved by the XIII National Congress of therapists (Moscow, November 21-23, 2018). © 2019, Stavropol State Medical University. All rights reserved